Citalopram STELLA 10 mg

Citalopram belongs to the group of selective serotonin reuptake inhibitors (SSRIs) that restores the balance of serotonin in brain.

Pack size Box of 30 tablets
Shelf-life 36 months
Composition Citalopram
Dosage forms and strengths Film-coated tablet: 10 mg
Product code :



  • Treatment of major depressive episodes.
  • Treatment of panic disorder with or without agoraphobia.


  • Adults:
    Major depressive episodes: A single dose of 20 mg daily, depend on response, may be increased to a maximum of 40 mg daily; treatment should continue until the patient has been free of symptoms for 4 – 6 months to give adequate protection against the possibility of a relapse.
    Panic disorder: A single dose of 10 mg for first week before increasing the dose to 20 mg daily, depend on response, may be increased to maximum 40 mg daily; continue treatment for several months.
  • Older people (> 65 years of age):
    Half of the recommended dose.
  • Reduced hepatic function mild – moderate or poor metabolisers regarding CYP2C19:
    10 mg daily for the first two weeks, may be increased to a maximum of 20 mg daily.
  • Stopping treatment:
    Gradually reduced over a period of at least one to two weeks.
    If intolerable symptoms occur following a dosage decrease/discontinuation of treatment: resuming the previously prescribed dose; continue decreasing the dose, but at a more gradual rate.
  • Reduced renal function
    Mild to moderate: Dosage adjustment is not necessary.
    Severe (ClCr < 20 ml/min): Do not use.
  • Children and adolescents under 18 years of age:
    Do not use.


Taken with or without food, but with fluid, either in the morning or in the evening.

  • Known hypersensitivity to any ingredient in the formulation.
  • The combination with linezolid unless there are facilities for close observation and monitoring of blood pressure.
  • Patients with know QT-interval prolongation or congenital long QT syndrome.
  • The co-administration with medicinal products that are known to prolong the QT-interval.
  • Citalopram should not be given to patients receiving monoamine oxidase inhibitors (MAOIs).

Very common

  • Agitation, nervousness;
  • Lethargy, insomnia, tremor, dizziness, headache, somnolence;
  • Abnormal accommodations;
  • Palpitations;
  • Dry mouth, nausea, constipation;
  • Increased sweating;
  • Asthenia.


  • Appetite decreased, weight decreased;
  • Libido decreased, abnormal orgasm (female), anxiety, confusional state, apathy, impaired concentration, abnormal dreams, memory loss;
  • Paraesthesia, sleeping disorders, migraine, taste disturbance, disturbance in attention;
  • Visual disturbance;
  • Tinnitus;
  • Tachycardia;
  • Hypotension, hypertension, orthostatic hypotension;
  • Diarrhoea, vomiting, dyspepsia, abdominal pain, flatulence, increased salivation;
  • Pruritus, rash;
  • Myalgia, arthralgia;
  • Polyuria, micturition disorder;
  • Impotence, ejaculation disorder, ejaculation failure, dysmenorrhea;
  • Fatigue, pyrexia.
  • Caution when using Citalopram STELLA 10 mg for patients with diabetes; unstable epilepsy (avoid using); controlled epilepsy; significant bradycardia, recent acute myocardial infarction/uncompensated heart failure; reduced kidney and liver function; angle-closure glaucoma or history of glaucoma; elderly patients; pregnancy (consideration of the benefit/risk); nursing women.
  • Electrolyte disturbances should be corrected before treatment with citalopram is started.
  • Risk of suicidal/suicide thoughts or clinical worsening.
  • Citalopram should be discontinued if there is an increase in seizure frequency; signs of cardiac arrhythmia; enter a manic phase in patients with manic – depressive illness; serotonin syndrome (rare).
  • Withdraw symptoms seen on discontinuation of treatment.
  • Concurrent administration of citalopram and ECT (electro-convulsive therapy).
  • There have been reports of prolonged bleeding time and/or bleeding abnormalities.
  • Treatment of psychotic patients with depressive episodes may increase psychotic symptoms.
  • Patients with rare hereditary problems of galactose intolerance, total lactase deficiency or glucose-galactose malabsorption should not take this medicine.
  • Patients should be aware of how they react to drug before driving or operating machinery.